BioMarin’s Pipeline Faces Skepticism As Analyst Questions Future Growth
BioMarin posts Q3 EPS of $0.91, nearly doubling last year’s $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts. Latest Ratings for BMRN Date Firm Action From To Feb 2022 Piper Sandler Maintains Overweight Nov 2021 Credit Suisse Maintains Outperform Nov 2021 Morgan Stanley Maintains